The effect of Chinese herbs and its effective components on coronary heart disease through PPARs-PGC1α pathway

Qiyan Wang1†, Chun Li2†, Qian Zhang1,3†, Yuanyuan Wang3, Tianjiao Shi3, Linghui Lu3, Yi Zhang2, Yong Wang1,3* and Wei Wang1,3*

Abstract

Background: DanQi pill (DQP) is prescribed widely in China and has definite cardioprotective effect on coronary heart disease. Our previous studies proved that DQP could effectively regulate plasma levels of high density lipoprotein (HDL) and low density lipoprotein (LDL). However, the regulatory mechanisms of DQP and its major components Salvianolic acids and Panax notoginseng saponins (DS) on lipid metabolism disorders haven’t been comprehensively studied so far.

Methods: Rat model of coronary heart disease was induced by left anterior descending (LAD) artery ligation operations. Rats were divided into sham, model, DQP treated, DS treated and positive drug (clofibrate) treated groups. At 28 days after surgery, cardiac functions were assessed by echocardiography. Expressions of transcription factors and key molecules in energy metabolism pathway were measured by reverse transcriptase polymerase chain reaction or western blotting.

Results: In ischemic heart model, cardiac functions were severely injured but improved by treatments of DQP and DS. Expression of LPL was down-regulated in model group. Both DQP and DS could up-regulate the mRNA expression of LPL. Membrane proteins involved in lipid transport and uptake, such as FABP4 and CPT-1A, were down-regulated in ischemic heart tissues. Treatment with DQP and DS regulated lipid metabolisms by up-regulating expressions of FABP4 and CPT-1A. DQP and DS also suppressed expression of cytochrome P450. Furthermore, transcriptional factors, such as PPARα, PPARγ, RXRA and PGC-1α, were down-regulated in ischemic model group. DQP and DS could up-regulate expressions of these factors. However, DS showed a better efficacy than DQP on PGC-1α, a coactivator of PPARs. Key molecules in signaling pathways such as AKT1/2, ERK and PI3K were also regulated by DQP and DS simultaneously.

Conclusions: Salvianolic acids and Panax notoginseng are the major effective components of DanQi pill in improving lipid metabolism in ischemic heart model. The effects may be mediated by regulating transcriptional factors such as PPARs, RXRA and PGC-1α.

Keywords: Components, Coronary heart disease, PPARs-PGC1α pathway, DanQi pill

* Correspondence: doctor_wangyong@163.com; wangwei_8@sina.cn
†Equal contributors
1 School of Life Sciences, Beijing University of Chinese Medicine, Beijing, 100029, China
Full list of author information is available at the end of the article

© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Coronary heart disease (CHD) induced by atherosclerosis remains one of the major threats to people’s health and one of the main causes of death, despite our better understanding of the pathophysiology of CHD and advances in treatment methods [1]. In developing countries, the incidence of CHD has been rising in recent years [2]. It’s of paramount importance to develop novel therapies for CHD so as to reduce the economic and health burden caused by it.

Managements of CHD include life style changes, medication and surgical procedures [3, 4]. Antihypertensive drugs such as ACEIs and lipid lowering drugs are the most commonly prescribed medications. Traditional Chinese medicine (TCM) has also been used to treat CHD for a long period of time. DanQi Pill (DQP), composed of Radix Salvia Miltiorrhiza (Danshen) and Panax notoginseng (Sanqi), is among the most commonly prescribed TCM [5] Salvianolic acids are the water soluble compounds extracted from Radix Salvia Miltiorrhizae [6, 7], and Panax notoginseng saponins are the major active components of Panax notoginseng [8, 9]. Exploration of the pharmacological mechanisms of DQP will provide insight into the treatment of CHD and development of new drugs.

Our previous studies proved that DQP could effectively regulate plasma levels of high density lipoprotein (HDL) and low density lipoprotein (LDL) in rat models of CHD [9]. DQP could also modulate cardiac energy metabolism that has been disturbed under ischemic conditions [10]. In ischemic heart disease, overall mitochondrial oxidative catalysis decreases while reliance on anaerobic glycolysis pathways is increased [11, 12]. Fatty acids oxidation was effectively improved by DQP, as was shown by up-regulated fatty acids transportation, uptake and metabolism. DQP exerts cardioprotective effect by improving energy supply of myocytes. However, the upstream transcriptional regulatory effects of DQP haven’t been studied yet. Furthermore, the effects of compound formula (DQP) and major components (Salvianolic acids and Panax notoginseng saponins, DS) haven’t been evaluated yet.

The peroxisome proliferator-activated receptor family (PPARα, β/δ and γ) of nuclear receptor transcription factors is an important regulator of cardiac metabolism [12]. The PPARs control myocardial metabolism by transcriptionally regulating genes encoding enzymes involved in fatty acid and glucose utilization [13, 14]. Peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) is transcriptional coactivator of the PPARs and is a key player in the control of myocardial metabolism. Activation of PGC-1α drives a strong induction of PPARs target genes encoding fatty acid oxidation enzymes [15]. In this study, we investigated the effects of DQP and the extracts of DQP (DS, Panax notoginseng saponins and Salvianolic acids) on PPARs and PGC-1α. The target genes of these transcriptional regulators involved in energy metabolism and down-stream signaling pathways were also detected. Rat model of ischemic coronary heart disease was applied in this work. This study will provide further insight into the mechanisms of traditional Chinese medicine in the management of CHD.

Methods

Animal groupings and induction of myocardial infarction

One hundred Sprague-Dawley (SD) male rats, with weight of 220 ± 10 g, were randomly divided into five groups: sham-operated, model, positive control drug (clofibrate) treated, solutions of DS treated and DQP treated groups. All the rats were purchased from Beijing Vital River Laboratory Animal Technology Co. Ltd, with the license number of SCXK2010 ~ 2011. The animal experiments were approved by the Animal Care Committee of Beijing University of Chinese Medicine. The rats were fed with regular diet for one week before surgery. Rats in the control group received sham operation while rats in the other groups underwent left anterior descending (LAD) artery ligation surgeries which induced models of ischemic heart disease. The operational procedures have been described in our previous studies [10, 16]. Briefly, left thoracotomies were performed after rats were anaesthetized by 1% pentobarbital sodium at the dosage of 50 mg/kg via intraperitoneal injection. LAD coronary arteries were then ligated with a 5–0 polypropylene suture. The thorax was closed after ligation. Rats in the sham group received the same procedures except that the coronary arteries were not ligated. From the second day after surgery, Rats were randomly divided into five groups: sham group fed with normal diet, model group, clofibrate group (positive control), DQP group and DS group fed with high fat diet for 28 days. Rats in the DQP group were treated with DQP aqueous solution (Tongren tang, Beijing, China, Series: 6128006) at the dosage of 1.5 mg/kg per day via oral gavage for 28 consecutive days [9]. In DS group, rats received solutions of salvianolic acid (SA) and Panax Notoginseng Saponins (PNS) at the dosage of 7.5 μg/kg and 82.5 μg/kg respectively. The dosage of SA and PNS were given according to their percentage contained in DQP. Rats in the positive control group received clofibrate aqueous solution at the dosage of 0.3 g/kg as reported previously. Animals in the sham and model groups were given a gavage of normal saline water for 28 days. The mortality rate of surgery was 22%. After surgery, 19(95%), 15(75%), 14(70%), 16(80%) and 14(70%) rats survived in sham, model, positive control drug treated, DS treated and DQP treated groups, respectively.
Measurement of cardiac functions

Echocardiography was applied to assess the cardiac functions at 28d after surgery using a Vevo 2100 (VisualSonics Inc, Toronto, Ontario, Canada). A PST 65A sector scanner (8-MHz probe) was employed, which generates two-dimensional images at a frame rate of 300 to 500 frames/s. The parameters of heart functions include: left ventricular end-systolic diameter (LVESd), left ventricular end-diastolic diameter (LVEDd), left ventricular end-diastolic volume (LVEDv), left ventricular end-systolic volume (LEVSv), ejection fraction (EF) and fractional shortening (FS). EF was calculated as follows: EF % = [(LVEDv - LVESv)/LVEDv] × 100%. FS was calculated using the equation: [(LVEDd - LVESd)/LVEDd] × 100%.

Evaluation of mRNA expressions of key molecules involved in lipid metabolism pathway

The mRNA expressions of Lipoprotein Lipase (LPL), cluster of differentiation 36 (CD36) and ATP-binding cassette transporter (ABCA1) were determined by reverse transcriptase polymerase chain reaction (RT-PCR). Total RNA was extracted using TRIzol Reagent (Gibco-BRL, Paisley, UK). The concentration of RNA was measured using Nano Drop 2000 (Thermo Scientific, USA), and the RNA was then transcribed to cDNA using the RevertAidTM First Stand cDNA Synthesis kit (Fermentas, LT). The reaction volume was 20 μl, containing 2 μl cDNA, 0.5 μl forward and 0.5 μl reverse primers, 10 μl Rox and 7 μl DEPC. For cDNAs analysis of LPL, ABCA1, CD36 and GAPDH, PCR conditions were set as follows: 15 s at 95 °C for denaturation, and 1 min at 55 °C for annealing and extension. 40 cycles were run for each gene. The sequences of the primers were shown at Table 1. Quantities of each gene were normalized to quantity of GAPDH mRNA.

Measurement of key proteins in energy metabolism pathways by western blot (WB)

Left ventricle homogenates were prepared for the analysis of protein levels. Briefly, the cardiac tissue was homogenized in RIPA buffer (50 mM Tris-HCl Ph7.4, 150 mM NaCl, 1% NP-40, 0.1%SDS) and total protein was extracted from this homogenate. The protein concentration in each sample extract was measured by a protein assay kit (Beijing PuLilai Gene Technology Co., Ltd, Beijing, China, lot number: P1511). Equal amounts of protein extracts (20 μg) were separated by 12.5% sodium dodecyl sulphate(SDS)-polyacrylamide gel electrophoresis (Bio-Rad, CA, U.S.A.) and transferred to nitrocellulose membranes electrophoretically (semidy transfer). Membranes were blocked with 5% non-fat dry milk in Tris-buffered saline (20 mM Tris, pH 7.6, 137 mM NaCl) with 0.1% Tween 20, washed, and then incubated with primary antibody. Primary antibodies employed included: goat polyclonal anti-glyceraldehyde-3-phosphate dehydrogenase(GAPDH) and anti- Peroxisome proliferator-activated receptor α (PPARα,ab8934), Peroxisome proliferator-activated receptor γ (PPARγ, SC7273), fatty acid binding protein (FABP, ab174673), Apolipoprotein A-I(ApoA-I,ab334707), Carnitine palmitoyltransferase 1A(CPT-1A, ab128568), 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR(H-300), SC-33827,SANTA), P450(Anti-Cytochrome P450 Reductase antibody, ab13513), peroxisome proliferator activated receptor coactivator 1 alpha(PGC-1α, ab54481), AKT1/2(ab6067), Phosphatidylinositol 3-kinase(Pi3K, ab151549) and extracellular signal-regulated kinase(ERK1/2, ab54230). The primary antibody was firstly incubated, and then the secondary antibodies (Santa Cruz Biotechnology Inc., CA, U.S.A.) was added. After being exposed to chemiluminescence developing agents, the protein levels and GAPDH in each sample were evaluated. The gel was scanned and the band densities were quantified. The band densities of proteins were normalized by the GAPDH band densities to determine their concentrations.

Statistical analysis

Data were presented as mean ± standard deviation. Differences among groups were analyzed by one-way analysis of variance (ANOVA) test. P values of smaller than 0.05 were considered as statistically significant. All statistical analyses were carried out by SPSS 17.0 software.

Results

Effects of DQP and DS on cardiac functions

Twenty eight days after surgery, ultrasonography was performed to evaluate heart functions in different groups of animals. LVEDd and LVEDs increased significantly in the model group compared with those in the sham.

Table 1  Nucleotide sequences of primers used in real-time PCR

| Gene (accession no.) | Primers | Nucleotide sequences 5′-3′ | Size (bp) | Temp (°C) |
|----------------------|---------|---------------------------|----------|-----------|
| LPL                  | Forward | CGCTCCATCATCATCTCTCTCTCTC | 18       | 57.3      |
|                      | Reverse | GGCTCTGACTGCTGGTGTGAT      | 18       | 55        |
| ABCA1                | Forward | GTGGTGTTCTCTCCCTGTTA       | 19       | 55.4      |
|                      | Reverse | TCTCCGCTCTTCTCTGTTAG       | 19       | 57.6      |
| CD36                 | Forward | GCCCTCTACACATACAGAGT        | 20       | 55.8      |
|                      | Reverse | CCACAGCCACATTGAGA          | 18       | 55        |
group, indicating that hypertrophy had developed as a result of ischemia in rats that underwent ligation surgery. EF and FS were reduced by 39.91% (P < 0.05) and 44.6% (P < 0.05) in the model group compared with those in the sham group, suggesting that cardiac functions were severely impaired in the model rats. After treatments with DQP, LVEDd and LVEDs were down-regulated by 32.14% (P < 0.05) and 28% (P > 0.05), and EF and FS were up-regulated by 15.03% (P < 0.05) and 63.40% (P < 0.05) in the DQP treatment group compared with those in the model group. In DS treatment group, EF and FS value were also improved compared with those in the model group (Table 2). These data indicated that DQP and DS could exert anti-hypertrophy and cardioprotective effects in ischemic heart.

**Effects of DQP and DS on proteins associated with lipid metabolism**

Expressions of lipoproteins and proteins involved in lipid metabolism were detected. ApoA-I, the major protein component of HDL, can promote cholesterol reversal transport by activating lecithin cholesterolacyltransferase (LCAT) [17]. Level of ApoA-I in model group (0.77 ± 0.07) was reduced compared as that in the sham group (1.00 ± 0.00) (P < 0.01). DQP and DS could increase plasma levels of ApoA-I (1.41 ± 0.11, 1.40 ± 0.11) (P < 0.01), promoting transportation of lipids from tissues to the liver for excretion (Fig. 1). Lipoprotein lipase (LPL) hydrolyzes triglycerides in lipoproteins and promotes cellular uptake of chylomicron remnants and cholesterol-rich lipoproteins [18]. Transcription level of LPL in model group was reduced significantly compared with that in the sham group (P < 0.01). After treatment with DQP and DS, LPL was up-regulated significantly (Table 3). ATP-binding cassette transporter (ABCA1), which is involved in cholesterol efflux pumping and formation of HDL, was down-regulated in model group compared with that in the sham group. Expression of ABCA1 was up-regulated after treatment with DS (Table 3).

Membrane molecules that are involved in lipid uptake into myocardial cells and mitochondria for oxidation were also detected. Key membrane proteins includes: CD36, α fatty acids binding protein 4 (FABP4), and carnitine palmityl transferase 1A (CPT-1A). Expression of CD36 and CPT-1A were significantly reduced in model group compared with those in the sham group (P < 0.05). Expression of FABP4 was also reduced in ischemic heart tissue, but the reduction showed no statistical significance. After treatment with DQP and DS for 28 days, expressions of both FABP4 and CPT-1A were up-regulated significantly, indicating that expressions of these molecules were activated and uptake of lipids into cardiac cell were improved (Table 3 and Fig. 1). No statistical differences were observed between effects of the DQP and DS.

**Effects of DQP and DS on cholesterol synthesis and metabolism**

HMGCR is the rate-limiting enzyme in cholesterol synthesis. Inhibiting HMGCR is an effective way in reducing plasma level of cholesterol and HMGCR is the target of statins [19]. In model group, HMGCR was up-regulated compared with sham group (P < 0.05). After treatment with DQP, HMGCR was significantly reduced (P < 0.001). However, DS had no effect on expression of HMGCR (P > 0.05) (Fig. 2).

Cytochrome P450 is involved in lipid modification and cholesterol metabolism [20]. P450 level was increased in model group compared with that in the sham group (P < 0.01). After treatment with DQP and DS, P450 level was reduced significantly compared with that in the model group (P < 0.01), indicating that DQP and DS could affect lipid metabolism by regulating levels of P450 enzymes (Fig. 2). The inhibition effects of DQP and DS on P450 were similar.

**Effects of DQP and DS on PPARs, RXRA and PGC-1α**

PPARs are the master transcription factors in energy metabolism [21, 22]. PPARα can bind with retinoic acid receptor alfa (RXRA) to form heterodimer, promoting transcription of fatty acid oxidation genes [23]. PGC-1α is a transcriptional coactivator that regulates the genes involved in energy metabolism [24, 25]. Expression changes of these factors in different groups of rats were detected. Western blot showed that PPARα, PPARγ, RXRA and PGC-1α were down-regulated by 24.25% (P > 0.05), 64.8% (P < 0.01), 42.09% (P < 0.05) and 61.97% (P < 0.05) in model group compared with those in sham-operated group, respectively. After treatment with DQP, expressions of PPARα, PPARγ, RXRA and PGC-1α were up-regulated by 141.31% (P < 0.001), 352.54% (P < 0.001), 123.71% (P < 0.001) and 103.41% (P < 0.05) in DQP

| Table 2 | Indicators of heart functions tested by Echocardiography in different groups of rats |
|---------|---------------------------------|
|         | Sham | Model | Positive drug | DQP | DS |
| LVEDd(cm)  | 0.64 ± 0.05 | 1.12 ± 0.21 | 1.08 ± 1.68 | 0.76 ± 0.06 | 0.83 ± 0.18 |
| LVEDs(cm)  | 0.41 ± 0.02 | 0.75 ± 0.05 | 0.48 ± 0.08 | 0.54 ± 0.08 | 0.64 ± 0.11 |
| EF         | 0.68 ± 0.06 | 0.41 ± 0.03 | 0.46 ± 0.06 | 0.47 ± 0.03 | 0.53 ± 0.01 |
| FS(%)      | 37.39 ± 5.19 | 20.71 ± 1.68 | 21.70 ± 5.78 | 33.84 ± 6.90 | 36.43 ± 8.76 |

*P < 0.05, **v.s. model group, P < 0.01*
group compared with those in model group, respectively. DS could also up-regulate expressions of these factors. PPARα, PPARγ, RXRA and PGC-1α were increased by 69.66% ($P < 0.05$), 640.89% ($P < 0.001$), 140.08% ($P < 0.001$) and 289.80% ($P < 0.001$) in DS group compared with those in model group, respectively (Fig. 3). The effects of DS on PPARγ, RXRA and PGC-1α were more remarkable compared with those of DQP, whereas DQP showed better effect in increasing expression of PPARα than DS.

**Effects of DQP and DS on PI3K/AKT and ERK1/2**

PI3K/AKT and mitogen-activated protein kinase (MAPK)/ERK1/2 are important cardio-protective survival pathways [26]. Expressions of PI3K and AKT1/2 were down-regulated by 63.41% ($P < 0.05$) and 60.23% ($P < 0.001$) in model rats compared with those in sham-operated rats, indicating that PI3K/AKT pathway was inhibited in ischemic heart tissue. Expression of ERK1/2 was also suppressed in model group compared to sham-operated group (Fig. 4). Treatments with DQP or DS could increase expressions of PI3K/AKT and ERK1/2, re-activating the signaling pathways. Compared with model group, expressions of PI3K, AKT1/2 and ERK1/2 in DQP group were up-regulated by 89.62% ($P > 0.05$), 96.39% ($P < 0.001$) and 138.67% ($P < 0.001$), respectively. In DS group, expressions of PI3K, AKT1/2 and ERK1/2 were up-regulated by 521.05% ($P < 0.001$), 189.82% ($P < 0.001$) and 213.96% ($P < 0.001$), respectively. The effects of DS on PI3K/Akt and ERK1/2 were more remarkable than DQP, suggesting that the cardio-protective effects of DS might be mediated by activating PI3K/Akt and ERK pathways (Fig. 4).

**Discussion**

In this study, we successfully induced rat model of ischemic coronary heart disease. Based on this model, we investigated the pharmacological mechanisms of DQP and its major components DS in the treatment of CHD. In the drug dosages we applied, cardiac functions were significantly improved as evidenced by reduced LVED and increased FS, suggesting that the current dosages were effective. Our major findings are as follows: 1) Both DQP and DS could exert cardioprotective effects under

![Fig. 1 Expressions of ApoA-1, FABP4 and CPT-1A in five groups of rats. Western blot showed that compared with model group, expressions of these three molecules were significantly up-regulated towards normal levels in DQP and DS groups. a Semi-quantitative expressions of ApoA-1 in different groups. b Semi-quantitative expressions of FABP4 in different groups. c Semi-quantitative expressions of CTP-1A in different groups. n = 6, * v.s. model group, $P < 0.05$; ** v.s. model group, $P < 0.01$](image)

|          | Sham     | Model    | Positive | DQP      | DS       |
|----------|----------|----------|----------|----------|----------|
| LPL      | $3.56 \pm 2.75^*$ | $0.15 \pm 0.07$ | $1.75 \pm 0.76^*$ | $1.05 \pm 0.60^*$ | $1.45 \pm 0.81^*$ |
| ABCA1    | $0.84 \pm 0.60^*$ | $0.27 \pm 0.28$ | $1.36 \pm 0.56^*$ | $1.30 \pm 0.95^*$ | $1.51 \pm 0.67^*$ |
| CD36     | $1.27 \pm 0.97^*$ | $0.76 \pm 0.45$ | $0.84 \pm 1.03$ | $0.77 \pm 0.30$ | $0.94 \pm 0.57$ |

*vs. model group, $^* P < 0.05$; $^{**} P < 0.01$
Fig. 2 Expressions of HMGCR and P450 in different groups. 
a Semi-quantitative expressions of HMGCR in different groups. 
b Semi-quantitative expressions of P450 in different groups. 
\( n = 6, * \) v.s. model group, \( P < 0.05; ** \) v.s. model group, \( P < 0.01; ## \) v.s. DQP group, \( P < 0.01 \)

Fig. 3 Expressions transcription regulators in five groups of rats. 
a Semi-quantitative expressions of PPAR-\( \alpha \) in different groups. 
b Semi-quantitative expressions of PPAR-\( \gamma \) in different groups. 
c Semi-quantitative expressions of RXRA in different groups. 
d Semi-quantitative expressions of PGC-1\( \alpha \) in different groups. 
\( n = 6, * \) v.s. model group, \( P < 0.05; ** \) v.s. model group, \( P < 0.01; ## \) v.s. DQP group, \( P < 0.01 \)
ischemic conditions. Heart functions were reserved in DQP and DS groups. 2) DQP and DS improved fatty acid oxidation in ischemic heart by up-regulating molecules involved in fatty acids transportation and uptake. 3) Both DQP and DS could up-regulate expressions of PPARα, PPARγ and RXRA. DQP was a better agonist of PPARα than DS, whereas the effects of DS on PPARγ, RXRA and PGC-1α were greater than those of DQP. 4) Expressions of PI3K/Akt and ERK1/2 were activated by DQP and DS. These results suggest that DQP and DS improve cardiac energy metabolism by up-regulating transcription factors such as PPARα, PPARγ and PGC-1α, thus providing cardioprotective effects under ischemic conditions. The effects of DQP and DS are comparable, indicating that DS are the major effective components in regulating energy metabolism.

Our previous studies illustrated that DanQi pill could regulate fatty acids metabolism in ischemic heart tissue. Not only can dyslipidemia cause coronary heart disease but coronary artery ligation can also induce dyslipidemia [9]. In this study, we re-confirmed that DQP could regulate components of apolipoprotein and key molecules involved in lipid transportation and uptake in ischemic heart model. Epidemiological studies showed that levels of HDL are inversely correlated with risk of cardiovascular events, whereas LDL levels are directly related to rate of these events [27, 28]. HDL protects against cardiovascular disease by regulating cholesterol efflux from tissues and modulating inflammation [29]. ApoA-1, the major protein component of HDL, is largely responsible for reverse cholesterol transport through the macrophage ATP-binding cassette transporter ABCA1 [30, 31]. Our study showed that expressions of ApoA-1 and ABCA1 were down-regulated in model group and treatments with DQP and DS up-regulated their expressions.

Several key molecules are involved in fatty acids transport and uptake by myocardiocyte. Fatty acid translocase/cluster of differentiation protein (CD36), a class of membrane protein, facilitates transport of long chain fatty acid into myocardiocyte [31, 32]. Plasma fatty acids are translocated into cardiac myocytes by FABP4 on the membrane and further transported into mitochondria by CPT-1. CPT-1A is one of the most abundant subtypes of CPT-1, which is the key enzyme in fatty acid oxidation process [33]. Fatty acid transport protein 4 (FATP4) is also involved in long- and very long-chain fatty acid uptake and facilitate acyl-CoA synthesis [34, 35]. These key molecules were down-regulated in model rats and treatments with DQP and DS significantly improved their expressions, suggesting that the lipid transport and uptake pathways could be regulated by DQP and DS. Furthermore, DQP could inhibit synthesis of cholesterol by
reducing expression of HMGCR. DS didn’t seem to have effect on HMGCR, indicating that the inhibitory effect on cholesterol synthesis may be mediated by components other than Salvianolic acids or Panax notoginseng saponins.

Fatty acids oxidation provides the majority of energies needed for cardiac contraction and this process is tightly regulated by transcription factors. We further investigated the effect of DQP and DS on transcriptional regulation of energy metabolism. The PPAR family is a class of transcription factors that regulate cardiac fuel metabolism at the gene expression level. The three PPAR family members (α, β/δ and γ) are uniquely suited to serve as transducers of developmental, physiological, and dietary cues that influence cardiac fatty acid and glucose metabolism [22]. The principal transcriptional regulator of fatty acid oxidation (FAO) enzyme genes is PPARα [20]. PPARy is a primary target for thiazolidinedione-structured insulin sensitizers like pioglitazone and rosiglitazone employed for the treatment of type 2 diabetes mellitus [36]. PGC-1α is transcriptional coactivator of the PPARs and is a key player in the control of mitochondrial metabolism. In cardiac myocytes, activation of PGC-1α drives a strong induction of PPARα target genes encoding FAO enzymes [14]. PGC-1α also coactivates other transcription factors, including estrogen-related receptors and the nuclear respiratory factor 1, to stimulate mitochondrial biogenesis and enhance expression of components of the electron transport chain [37]. In ischemic heart disease, the expression and/or DNA binding activity of the PPARα-RXR complex is markedly diminished by hypoxia, which results in decreased expression of genes encoding enzymes involved in mitochondrial FAO and oxidative phosphorylation pathways [38, 39]. The role of PPARs in ischemia is controversial. Some studies found that chronic activation of PPARα is detrimental to cardiac recovery after ischemia and PPARy activator was associated with increased mortality post-myocardial infarction in rats [40–42]. In our study, we found that expressions of PPARα, PPARγ, RXRA and PGC-1α were all down-regulated in ischemic model group. After treatments with DQP or DS for 28 days, the expressions of these transcriptional factors were up-regulated compared with those in the model group. DQP showed better effect on PPARα, whereas DS seemed to be more effective in up-regulating PPARy and PGC-1α. The different effects exertyed by DQP and DS may be due to complex interactions of different components in DQP compound [43]. These results demonstrated that up-regulating transcription factors targeting energy metabolism are cardio-protective under ischemic conditions. Components of DS may serve as ligand activators of PPARs. Besides DS, other compounds in DQP may also activate expressions of PPARα, as DQP improved PPARα expression in a more remarkable way. The exact mechanism by which DQP up-regulates PPARs warrants further studies. The active compounds in DQP, other than DS, also need further investigation.

The potential effects of DQP and DS on signaling pathway were also studied. It is widely accepted that phosphatidylinositol 3-kinase (PI3K) signaling to Akt is an important regulator of many cellular processes including proliferation, apoptosis and nitric oxide synthesis [44]. PI3K also increases cardiac fatty acid oxidative capacity [45]. Activation of PI3K/Akt pathway has been shown to play a key role in myocardial preconditioning [46]. PI3K signaling cascade reduces myocardial damage after ischemia by recruiting multiple endogenous cardioprotective pathways. ERK1/2 belongs to the MAPKs family and activation of ERK1/2 in cardiac myocytes serves as a defense mechanism against ischemic stress stimuli [47]. In this study, we found that expressions of PI3K, Akt1/2 and ERK1/2 were all reduced in model rats, and administrations of DQP and DS increased the expressions of these molecules, indicating that activation of PI3K/Akt and ERK1/2 is protective under ischemic conditions and DQP could activate the signaling pathway.

Conclusions

DS are the major effective components of DQP in improving energy metabolism in ischemic heart disease model. The effects may be mediated by regulating transcriptional factors such as PPARs, RXRA and PGC-1α. Further study into the pharmacological mechanisms of Salvianolic acids and Panax notoginseng will provide insight into the discovery of new drugs targeting PPARs and PGC-1α and new strategies in the management of cardiovascular diseases.

Abbreviations

ABC1A: ATP-binding cassette transporter; ApoA-I: Apolipoprotein A-I; CD36: Cluster of differentiation 36; CHD: Coronary heart disease; CPT-1A: Carnitine palmitoyltransferase 1A; DQP: Danshensu pills; DS: Panax notoginseng saponins; EF: Ejection fraction; ERK1/2: Extracellular signal-regulated kinase; FABP: Fatty acid binding protein; FS: Fractional shortening; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; HDL: High density lipoprotein; HMGCR: 3-hydroxy-3-methyl-glutaryl-CoA reductase; LAD: Left anterior descending; LCAT: Lecithin cholesterol acyltransferase; LDL: Low density lipoprotein; LEVS: Left ventricular end-systolic volume; LVESd: Left ventricular end-diastolic diameter; TCM: Traditional Chinese medicine

Funding

This study was financially supported by the Grants from the Beijing Natural Science Foundation (No.7142099), National Natural Science Foundation of China (81473456, 81470191, 81303298, 81503379, 81673712 and 81530100), Fok Ying Tung Education Foundation (No. 151044) and excellent young scientist foundation of BUCM (2015-JYB-XYQ001, 2015-JYB-QNJSZX001 and No.2016-JYB-XJ003).
Availability of data and materials
Data are all contained within the paper.

Authors’ contributions
QW CL TS carried out experiment studies. QW and YW drafted the manuscript. QZ YW participated in the echocardiography. LL YZ participated in the design of the study and performed the statistical analysis. WW YW conceived of the study. All authors read and approved the final manuscript.

Competing interests
The authors declared that they did not have any commercial or associative interest that represented a conflict of interest in connection with the work submitted.

Consent for publication
Not applicable.

Ethics approval and consent to participate
All the surgical and experimental procedures were performed with the approval of ethical committee of Beijing University of Chinese Medicine, Beijing, China (2014–15), which reviewed the procedures based on NIH Guidelines.

Author details
1 School of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China. 2 Modern Research Center for Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100102, China. 3 School of Basic Medical Science, Beijing University of Chinese Medicine, Beijing 100209, China.

Received: 8 June 2016 Accepted: 5 December 2016
Published online: 12 December 2016

References
1. Go AS, et al. Executive summary: heart disease and stroke statistics—2014 update a report from the American Heart Association. Circulation. 2014;129(3):399–410.
2. Wong MC, Zhang De X, Wang HH. Rapid emergence of atherosclerosis in Asia: a systematic review of coronary atherosclerotic heart disease epidemiology and implications for prevention and control strategies. Curr Opin Lipidol. 2015;26(4):257–63.
3. LaRosa JC. Prevention and treatment of coronary heart disease: who benefits? Circulation. 2001;104(14):1688–92.
4. Sheridan S, Let al. A randomized trial of an intervention to improve use and adherence to effective coronary heart disease prevention strategies.BMC Health Services Research. 2011;11(1):1–10.
5. Wang Y, et al. DanQi Pill protects against heart failure through the arachidonic acid metabolism pathway by attenuating different cyclooxygenases and leukotrienes B4. BMC Complement Altern Med. 2014;1467.
6. Ho JH, Hong CY. Salvianolic acids: small compounds with multiple mechanisms for cardiovascular protection. J Biomed Sci. 2011;18:30.
7. Chen J, et al. Separation and identification of water-soluble salvianolic acids from Salvia miltiorrhiza Bunge by high-speed counter-current chromatography and ESI-MS analysis. Talanta. 2006;69(1):172–9.
8. Liu P, et al. A rapid method for chemical fingerprint analysis of Panax notoginseng powders by ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. Chin J Nat Med. 2015;13(6):471–80.
9. Yao CL, et al. Simultaneous quantitation of five Panax notoginseng saponins by multi heart-cutting two-dimensional liquid chromatography: Method development and application to the quality control of eight Notoginseng containing Chinese patent medicines. J Chromatogr A. 2015;1402:71–81.
10. Wang Y, et al. DanQi Pill regulates lipid metabolism disorder induced by myocardial ischemia through FATP-CPTI pathway. BMC Complement Altern Med. 2015;15:28.
11. van der Vusse GJ, van Bilsen M, Glatz JF. Cardiac fatty acid uptake and transport in health and disease. Cardiovasc Res. 2000;45(2):279–93.
12. Finck BN. The PPAR regulatory system in cardiac physiology and disease. Cardiovasc Res. 2007;73(2):269–77.
13. Gilde AJ, et al. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res. 2003;93(5):518–24.
14. Djourabchi F, et al. The role of the peroxisome proliferator-activated receptor alpha (PPAR alpha) in the control of cardiac lipid metabolism. Prostaglandins Leukot Essent Fatty Acids. 1999;60(5):633–45.
15. Lehman JL, et al. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest. 2000;106(7):847–56.
16. Wang J, et al. Mechanism of QSYQ on anti-apoptosis mediated by different subtypes of cyclooxygenase in AMI induced heart failure rats. BMC Complement Altern Med. 2015;15:352.
17. Alexander ET, et al. Influence of apolipoprotein A-I domain structure on macrophage reverse cholesterol transport in mice. Arterioscler Thromb Vasc Biol. 2011;31(2):320–7.
18. Obunike JC, et al. Cellular differences in lipoprotein lipase-mediated uptake of low density lipoproteins. J Biol Chem. 1994;269(18):3129–35.
19. Medina MW. The relationship between HMGCGR genetic variation, alternative splicing, and statin efficacy. Discov Med. 2010;9(49):495–9.
20. Schmidt K, et al. Cholesterol metabolism: the main pathway acting downstream of cytochrome P450 oxidoreductase in skeletal development of the limb. Mol Cell Biol. 2009;29(10):2716–29.
21. Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med. 2000;10(6):238–45.
22. Madrazo JA, Kelly DP. The PPAR trio: regulators of myocardial energy metabolism in health and disease. J Mol Cell Cardiol. 2008;46(6):985–78.
23. Garcia-Rojas P, et al. Induction of peroxisomal proliferator-activated receptor gamma and peroxisomal proliferator-activated receptor coactivator 1 by unsaturated fatty acids, retinoic acid, and carotenoids in prepycocytes obtained from bovine white adipose tissue.1 J Anim Sci. 2010;88(5):1801–8.
24. Duncan JG, Finck BN. The PPARalpha-PGC-1alpha Axis Controls Cardiac Energy Metabolism in Healthy and Diseased Myocardium. PPAR Res. 2008;2008:253817.
25. Liang H, Wang WFC. PGC-1alpha: a key regulator of energy metabolism. Adv Physiol Educ. 2006;30(4):145–51.
26. Hu Y, et al. Cardioprotection induced by hydrogen sulfide preconditioning involves activation of ERK and PI3K/Akt pathways. Pflugers Arch. 2008;455(6):607–16.
27. Gordon T, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62(5):707–14.
28. Di Angelantonio E, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993–2000.
29. Navab M, et al. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011;8(4):222–32.
30. Shao B. Site-specific oxidation of apolipoprotein A-I impairs cholesterol export by ABCA1, a key cardioprotective function of HDL. Biochim Biophys Acta. 2012;1823(13):490–501.
31. Smith SK, et al. FAT/CD36 is located on the outer mitochondrial membrane, upstream of long-chain acyl-CoA synthetase, and regulates palmitate oxidation. Biochem J. 2011;437(1):125–34.
32. He J, et al. The emerging roles of fatty acid transloce/CD36 and the aryl hydrocarbon receptor in fatty liver disease. Exp Biol Med (Maywood). 2011;236(10):1116–21.
33. Bruce CR, et al. Overexpression of caninme palmitoyltransferase-I in skeletal muscle is sufficient to enhance fatty acid oxidation and improve high-fat diet-induced insulin resistance. Diabetes. 200958(3):550–8.
34. Hermann T, et al. Mouse fatty acid transport protein 4 (FATP4): characterization of the gene and functional assessment as a very long chain acyl-CoA synthetase. Gene. 2001;270(1–2):31–40.
35. Half AM, et al. Enzymatic properties of purified murine fatty acid transport protein 4 and analysis of acyl-CoA synthetase activities in tissues from FATP4 null mice. J Biol Chem. 2005;280(12):11948–54.
36. Balakumar P, Kathuria S. Submaximal PPARgamma activation and downregulation of low density lipoproteins. J Biol Chem. 1994;269(18):3129–55.
37. Finck BN. The PPARalpha-PGC-1alpha Axis Controls Cardiac Energy Metabolism in Healthy and Diseased Myocardium. PPAR Res. 2008;2008:253817.
38. Liang H, Wang WFC. PGC-1alpha: a key regulator of energy metabolism. Adv Physiol Educ. 2006;30(4):145–51.
39. Sack MN, Kelly DP. The energy substrate switch during development of heart failure: gene regulatory mechanisms (Review). Int J Mol Med. 1998;1(1):17–24.
40. Sambandam N, et al. Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia. Am J Physiol Heart Circ Physiol. 2006;290(1):H87–95.
41. Lygate CA, et al. The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiovasc Res. 2003;58(3):632–7.
42. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–71.
43. Venkataramanan R, Komoroski B, Strom S. In vitro and in vivo assessment of herb drug interactions. Life Sci. 2006;78(18):2105–15.
44. Blanes MG, et al. Phosphorylation of tyrosine 801 of vascular endothelial growth factor receptor-2 is necessary for Akt-dependent endothelial nitric-oxide synthase activation and nitric oxide release from endothelial cells. J Biol Chem. 2007;282(14):10660–9.
45. O’Neill BT, et al. A conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochondrial adaptations that accompany physiological cardiac hypertrophy. Cell Metab. 2007;6(4):294–306.
46. Hausenloy DJ, et al. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol. 2005;288(2):H971–6.
47. Yue TL, et al. Inhibition of extracellular signal-regulated kinase enhances Ischemia/Reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res. 2000;86(6):692–9.